DK1326628T3 - Kemokinmutanter til behandling af dissemineret sklerose - Google Patents

Kemokinmutanter til behandling af dissemineret sklerose

Info

Publication number
DK1326628T3
DK1326628T3 DK01986265T DK01986265T DK1326628T3 DK 1326628 T3 DK1326628 T3 DK 1326628T3 DK 01986265 T DK01986265 T DK 01986265T DK 01986265 T DK01986265 T DK 01986265T DK 1326628 T3 DK1326628 T3 DK 1326628T3
Authority
DK
Denmark
Prior art keywords
treatment
disseminated sclerosis
chemokine mutants
chemokine
mutants
Prior art date
Application number
DK01986265T
Other languages
Danish (da)
English (en)
Inventor
Amanda Proudfoot
Timothy N C Wells
Marie Kosco-Vilbois
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of DK1326628T3 publication Critical patent/DK1326628T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01986265T 2000-10-04 2001-10-03 Kemokinmutanter til behandling af dissemineret sklerose DK1326628T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00121665 2000-10-04
PCT/EP2001/011428 WO2002028419A2 (en) 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
DK1326628T3 true DK1326628T3 (da) 2004-08-09

Family

ID=8170011

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01986265T DK1326628T3 (da) 2000-10-04 2001-10-03 Kemokinmutanter til behandling af dissemineret sklerose

Country Status (31)

Country Link
US (1) US7402303B2 (zh)
EP (1) EP1326628B1 (zh)
JP (1) JP3908165B2 (zh)
KR (1) KR100837898B1 (zh)
CN (1) CN1285381C (zh)
AR (1) AR030854A1 (zh)
AT (1) ATE265222T1 (zh)
AU (2) AU2002215919B2 (zh)
BG (1) BG66137B1 (zh)
BR (1) BR0114407A (zh)
CA (1) CA2423616C (zh)
CZ (1) CZ303409B6 (zh)
DE (1) DE60103078T2 (zh)
DK (1) DK1326628T3 (zh)
EA (1) EA006137B1 (zh)
EE (1) EE05174B1 (zh)
ES (1) ES2217199T3 (zh)
HK (1) HK1062811A1 (zh)
HR (1) HRP20030215B1 (zh)
HU (1) HUP0302194A3 (zh)
IL (2) IL155178A0 (zh)
MX (1) MXPA03003008A (zh)
NO (1) NO330278B1 (zh)
PL (1) PL204231B1 (zh)
PT (1) PT1326628E (zh)
RS (1) RS50738B (zh)
SI (1) SI1326628T1 (zh)
SK (1) SK287523B6 (zh)
UA (1) UA77950C2 (zh)
WO (1) WO2002028419A2 (zh)
ZA (1) ZA200302315B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525089A (ja) 2001-12-17 2005-08-25 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ ケモカイン・アンタゴニストとして作用するケモカイン突然変異体
DE60303929T2 (de) * 2002-04-04 2006-08-10 Applied Research Systems Ars Holding N.V. Chemokin-muntanten mit verbesserter oraler bioverfügbarkeit
WO2004062688A2 (en) * 2002-12-23 2004-07-29 Applied Research Systems Ars Holding N.V. Use of cc-chemokine mutants against liver diseases
DE602004018014D1 (de) * 2003-10-22 2009-01-08 Serono Lab Cxcl8-antagonisten
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
DE60304435T2 (de) * 2004-01-19 2006-08-24 Ares Trading S.A. Verfahren zur Reinigung von in Bakterien exprimierten Proteinen
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
EP1760110B1 (en) * 2005-09-03 2011-11-02 Samsung SDI Co., Ltd. Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
MX2010001307A (es) 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
AU2011213559B2 (en) * 2010-02-08 2015-05-07 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same
CA3101052A1 (en) 2018-05-28 2019-12-05 ORION Biotechnology Switzerland Sarl Methods of inhibiting cerebral inflammation
WO2022093857A1 (en) * 2020-10-26 2022-05-05 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
DE69832216T2 (de) * 1997-12-23 2006-05-24 Fondazione Centro San Raffaele Del Monte Tabor RANTES-Mutanten und therapeutische Anwendungen davon
AU2740900A (en) * 1999-01-29 2000-08-18 Millennium Pharmaceuticals, Inc. Method of treating demyelinating inflammatory disease using ccr1 antagonists

Also Published As

Publication number Publication date
SK4062003A3 (en) 2003-08-05
HRP20030215B1 (en) 2011-09-30
HK1062811A1 (en) 2004-11-26
HUP0302194A3 (en) 2005-12-28
CN1477969A (zh) 2004-02-25
PT1326628E (pt) 2004-09-30
AU1591902A (en) 2002-04-15
MXPA03003008A (es) 2003-07-14
ES2217199T3 (es) 2004-11-01
EP1326628B1 (en) 2004-04-28
NO330278B1 (no) 2011-03-21
WO2002028419A2 (en) 2002-04-11
SI1326628T1 (en) 2004-10-31
PL204231B1 (pl) 2009-12-31
RS50738B (sr) 2010-08-31
CA2423616C (en) 2010-03-16
WO2002028419A3 (en) 2002-06-13
NO20031525L (no) 2003-04-03
SK287523B6 (sk) 2011-01-04
DE60103078D1 (de) 2004-06-03
EA006137B1 (ru) 2005-10-27
NO20031525D0 (no) 2003-04-03
ATE265222T1 (de) 2004-05-15
PL362350A1 (en) 2004-10-18
EA200300439A1 (ru) 2003-08-28
BR0114407A (pt) 2003-07-29
UA77950C2 (en) 2007-02-15
US7402303B2 (en) 2008-07-22
HUP0302194A2 (hu) 2003-10-28
CZ2003947A3 (cs) 2003-11-12
US20040101509A1 (en) 2004-05-27
AU2002215919B2 (en) 2005-11-24
JP2004510426A (ja) 2004-04-08
IL155178A (en) 2009-07-20
JP3908165B2 (ja) 2007-04-25
AR030854A1 (es) 2003-09-03
BG107685A (bg) 2003-11-28
CA2423616A1 (en) 2002-04-11
HRP20030215A2 (en) 2005-02-28
CZ303409B6 (cs) 2012-09-05
IL155178A0 (en) 2003-11-23
DE60103078T2 (de) 2005-04-07
EE05174B1 (et) 2009-06-15
YU25703A (sh) 2006-05-25
EE200300139A (et) 2003-06-16
ZA200302315B (en) 2004-03-25
BG66137B1 (bg) 2011-07-29
EP1326628A2 (en) 2003-07-16
KR100837898B1 (ko) 2008-06-13
KR20030034238A (ko) 2003-05-01
CN1285381C (zh) 2006-11-22

Similar Documents

Publication Publication Date Title
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK0967214T3 (da) Intranasale formuleringer til behandling af seksuelle forstyrrelser
DK1073658T3 (da) Pyrazolopyrimidinon-cGMP PDE5-inhibitorer til behandling af sexualforstyrrelse
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
MA25996A1 (fr) Inhibiteurs de phosphodiesterase 4.
FI20001993A0 (fi) Puhelinneuvottelu
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1326628T3 (da) Kemokinmutanter til behandling af dissemineret sklerose
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK1345598T3 (da) Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser
DK1187833T3 (da) Fremgangsmåde til fremstilling af thiamethoxam
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1292586T3 (da) Fremgangsmåde til fremstilling af pyrazolopyrimidinoner
EE200200693A (et) Interferoon hulgiskleroosi raviks
DK1390364T3 (da) Aryl-8-azabicyclo[3.2.1]octaner til behandling af depression
DK1468686T3 (da) S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
DK1286940T3 (da) Fremgangsmåde til fluormethylering af alkoholer
ES1045691Y (es) Ducha
DK1311260T3 (da) Lipaseinhibitorer til behandling af dyspepsi
DK1242089T3 (da) Anvendelse af adatanserin til behandling af akutte neutodegenerative lidelser
IT251123Y1 (it) Dispositivo per l'introduzione di supposte .
DK1144382T3 (da) Fremgangsmåde til fremstilling af 3-substituerede 1,5-diarylpyrazoler
DK1200350T3 (da) Fremgangsmåde til fremstilling af kvasi-krystallinske boehmitter